NEW YORK – Spartan Bio said this week that it has tapped Cardinal Health for US distribution of its CYP2C19 genotyping assay for mutations that affect approximately 15 percent of all prescribed drugs.
NEW YORK – Spartan Bio said this week that it has tapped Cardinal Health for US distribution of its CYP2C19 genotyping assay for mutations that affect approximately 15 percent of all prescribed drugs.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.